Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGAV | P06756 | 19/20 | 0.47 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.41 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29797060 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL21294608 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL21294589 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20139505 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20139506 | 1.00 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20140148 | 0.86 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20140505 | 0.81 | ITGAV (0.48) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20140792 | 0.79 | ITGAV (0.36) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL21294610 | 0.78 | ITGAV (0.72) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL20140510 | 0.78 | ITGAV (0.73) | ITGB3ITGAVITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | claimed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | claimed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ITGB6 15/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGB3 1/4885ITGAV 3/4885ITGB6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.